CHAPEL HILL, N.C., Jan. 16 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a
pharmaceutical development company with a portfolio of product candidates for
the treatment of migraine, announced that its president and chief executive
officer, John R. Plachetka, Pharm. D., has been elected chairman of POZEN Inc.
Plachetka, who will continue as president and chief executive officer,
succeeds Jacques F. Rejeange who will remain on the board of directors.
"Jacques has provided invaluable guidance over the last year," said
Plachetka. "We thank him for leading the company through a period of rapid
growth and its initial public offering. We are pleased that he is committed
to remain on the board and we intend to draw on his wealth of experience."
Rejeange commented, "It has been a privilege to serve as chairman and
contribute to POZEN's successes to date. I look forward to remaining actively
involved and contributing to the company's future successes."
The company also announced that Dr. Peter J. Wise, M.D., a co-founder of
POZEN and a current member of the board, has been elected to the newly created
position of vice chairman. Plachetka said, "We have benefited greatly from
Peter's expertise in drug development and he will continue to be instrumental
in our future product development activities. His expertise in this area and
his leadership abilities will make a significant contribution to our continued
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. The company's initial focus is
migraine, where it has built a robust portfolio of four product candidates
through a combination of innovation and in-licensing. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN."
POZEN is on the Internet at www.pozen.com
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick